U.S. Stem Cell, Inc. (USRM) news
SUNRISE, FL – Feb 23, 2021 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce the efforts of NorthStar Biotech Group and USRM Board Members to reinvest in U.S. Stem Cell, Inc.
On May 9, 2018, the U.S. Department of Justice, at the request of the U.S. Food and Drug Administration (FDA), filed suit against U.S. Stem Cell, Inc. and others to enjoin
SUNRISE, FL – June. 8th, 2021 – U.S. Stem Cell, Inc. (OTC: USRM), a corporation that has historically focused on the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products in both human and veterinary stem cell processes , has received the results of the Appeal from the United States 11th District Court for the Southern District of Florida.
Since May 9th, 2018, U.S. Stem Cell, as